Nearly one third of patients with ulcerative colitis who received an experimental Pfizer Inc. medicine in a clinical trial were in remission after a year of treatment, the drugmaker said on Tuesday.
https://www.pharmalive.com/wp-content/uploads/2022/02/U.S.-considers-authorization-of-first-COVID-vaccine-for-children-under-5-Reuters-2-1-22.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-24 07:00:062022-05-24 11:53:25Pfizer ulcerative colitis drug leads to remission in a third of patients – study
